|This article needs additional citations for verification. (May 2011)|
|Focus||Staffing, regulatory science|
|Method||Partnerships between public and private organizations|
|Mission||Promote regulatory science for Food and Drug Administration|
The Reagan-Udall Foundation is a private nonprofit (501c3) organization, created to support the mission of the U.S. Food and Drug Administration (FDA) to help equip FDA staff with the highest caliber, regulatory science and technology in order to enhance the safety and effectiveness of FDA regulated products. Although it was mandated by Congress in the Food and Drug Administration Amendments Act of 2007 to help support and promote FDA's regulatory science priorities, it is independent of the agency, with its own Board of Directors, staff and research agenda. The Reagan-Udall Foundation creates public-private partnerships to advance research in regulatory science, enhance medical decision making, and promote innovation. It also advances regulatory science through fellowships and other training programs, both for private scientists and for FDA staff.
Current activities and projects
The Reagan-Udall Foundation is collaborating with FDA in several high-priority scientific areas identified as part of the agency's innovation strategy. These include food safety, novel approaches in the development of therapies to fight tuberculosis, and methodologies for post-market product surveillance. Two specific examples:
1) Funded by the Bill & Melinda Gates Foundation, the Reagan-Udall Foundation is an active participant in the Critical Path to TB Drug Regiments (CPTR), a global initiative co-founded by the Bill & Melinda Gates Foundation, the Critical Path Institute, and the TB Alliance in March 2010 to accelerate the development of new tuberculosis (TB) treatment regimens. The Foundation's role is to convene and facilitate collaboration and dialogue between the CPTR team and a broad range of international TB stakeholders including regulatory and academic scientists, drug developers, advocates, and other NGOs, to identify, prioritize and work toward resolving regulatory science issues and challenges.
2) Funded by the Susan G. Komen for the Cure, the Reagan-Udall Foundation is convening a Systems Toxicology Project with the ultimate goal of directly identifying common biological intermediates for toxicity in two classes of oncology drugs, then correlating them to an adverse event. This could enable future research within the drug class to mitigate toxic effects through dosing modification, alternative treatments, or potentially develop a new regulatory tool that would assist in future drug safety evaluation. By having an independent, third party convener, like the Reagan-Udall Foundation, multiple companies can be readily involved, along with toxicologists, oncologists and other scientists from the FDA, National Institutes of Health and academia.
The Reagan-Udall Foundation is managed by Jane Reese-Coulbourne, executive director, and overseen by a 14-member board that includes representatives from (2) patient/consumer advocacy groups, (3) academic research institutions, no more than (4) from the general, pharmaceutical, device, food, cosmetic and biotechnology industries, (1) health care providers and (4) at large representatives with relevant expertise and experience. As required by statute, two leading government scientists - the Commissioner of the FDA and the Director of the National Institutes of Health are ex officio members of the Board. The RUF has numerous provisions in place to protect against conflicts and undue influence. Board members are prohibited from participating in matters in which they have a financial interest and must disclose their financial interest in entities doing business with the Foundation and in entities regulated by the FDA. Additionally, conflicts protections are required for each individual project the Foundation undertakes. All projects are reviewed by the Board of Directors and are subject to an independent review.
Finally, the Foundation is prohibited from participating in regulatory matters or offering advice to FDA on policy matters.
- Regulatory Science
- Food and Drug Administration
- Food and Drug Administration Amendments Act of 2007
- Mark McClellan
- Ellen V. Sigal
- Tachi Yamada
- Phillip Allen Sharp
- Diana Zuckerman
- "FDA Announces Board Members of Reagan-Udall Foundation". Fda.gov. Retrieved 2011-05-17.